Aap Implantate Ag · XETR:AAQ1
Aap Implantate — Warburg Small Cap Selection Conference 2018
24 slides from Aap Implantate's conference presentation, May 16, 2018
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation Warburg Small Cap Selection Conference Making Trauma Treatment Better and Cost-Effective Bruke Seyoum Alemu, CEO Frankfurt am Main, May 16, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap at a Glance
aap at a Glance Pure player in trauma Orthopedic company focused on trauma addressing unmet needs in trauma surgery: ➢ Simplify operation techniques for im- and explantation of implants ➢ Reduce surgical site infections (SSI) caused by implants ➢ Avoid second operations by using resorbable metal imp
Slide 4: Sustainability & Value creation
Our Balanced Portfolio of Innovations Addressing unmet needs and challenges High Incremental innovations Breakthrough innovations Sustainability & Value creation Sell more to existing Reach new customers Shift existing markets Create new market Low customers Impact on market Our source of value crea
Slide 5: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® Unmet need / challenge: Simplify operation techniques for im- and explantation IP-protected Our response: Locking compression technology by aap ➢ Angular stable compression in one step ➢ Strong clinical evidence of no cold-welding ➢ Comprehensive plates and screws portf
Slide 6: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® ➢ Comprehensive ➢ Patented ➢ High Quality ➢ Clinical & Economical Advantage Indication Coverage > 90% 6
Slide 7: Surgical Site Infections (SSI)
Surgical Site Infections (SSI) Outlining the market potential for aap’s silver coating technology ➢ SSI are burdening global economies enormously ➢ “SSI is the most frequent type of health care associated infections (HAI) in low- and middle-income countries affecting up to 1/3 of patients who have u
Slide 8: Platform Technology – Silver Coating
Platform Technology – Silver Coating Unmet need / challenge: Reduce surgical site infections (SSI) caused by implants IP-protected Our response: Antibacterial silver coating by aap ➢ Stable coating with high antibacterial efficacy and biocompatibility ➢ Cost-effective coating technology ➢ Platform t
Slide 9: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants Unmet need / challenge: Avoid second operations by using resorbable metal implants IP-protected Our response: Coated Resorbable Magnesium Implant Technology by aap ➢ Good biomechanical properties combined with a moderate and controllable resorption rate ➢ Cos
Slide 10: LOQTEQ® – Roadmap
LOQTEQ® – Roadmap Addressing unmet needs in trauma through innovations 10
Slide 11: aap – Sum of the Parts
aap – Sum of the Parts Strategic framework of the hidden value Sum of the parts strongly indicates ➢ Potential to be first mover in trauma application substantial upside for value creation ➢ Wide range of potential applications outside trauma ➢ Increasing interest by global companies to partner, Mar
Slide 12: aap’s Equity Story – Pure Player in Trauma
aap’s Equity Story – Pure Player in Trauma Why invest in aap? Making Trauma Treatment Better and Cost-Effective ➢ Innovative IP-protected products and platform technologies addressing unmet needs and challenges in trauma ➢ LOQTEQ®: Addressing the fastest growing trauma segments ➢ Silver Coating: Add
Slide 13: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 14: Appendix
Appendix qos
Slide 15: Key results and progress FY/2017
Key results and progress FY/2017 ➢ Sales and Earnings ▪ Trauma sales growth of 20% to EUR 10.6 million (FY/2016: EUR 8.9 million) ▪ Sales with EUR 10.9 million (+4% vs. FY/2016) in line with guidance ▪ All major markets contributed to sales growth: North America (+26% in total, distribution business
Slide 16: Financial Figures FY/2017 (1/2)
Financial Figures FY/2017 (1/2) (in KEUR) Sales FY/2017 FY/2016 Change Trauma 10,648 8,877 +20% Germany 2,428 2,352 +3% North America 3,071 2,436 +26% North America Distributors 2,491 1,464 +70% North America Global Partners 580 972 -40% International 5,149 4,089 +26% Other (mainly discontinued acti
Slide 17: Financial Figures FY/2017 (2/2)
Financial Figures FY/2017 (2/2) (in EUR million) Capital Structure 31/12/2017 31/12/2016 Change Total Assets 50.5 63.9 -21% Equity Ratio 84% 86% Cash Flow and Investments FY/2017 FY/2016 Change Operative cash flow -5.4 -7.2 +25% Total investing activities 2.1 2.5 -17% Cash Structure 31/12/2017 31/12
Slide 18: Silver Coating Technology – Update
Silver Coating Technology – Update* Substantial progress regarding preparations for human clinical study ➢ aap is in continued intensive preparation of various applications at authorities involved for clinical study; in addition currently intensive work on validation of relevant internal processes,
Slide 19: Shareholder Structure
Shareholder Structure (As of 14/05/2018, shareholdings in aap ≥ 3%) ➢ High degree of stability with a base of long-term oriented investors ➢ Market Cap of approx. EUR 51 million* 15.83% Ratio Capital Management B.V., Netherlands Noes Beheer B.V., Netherlands Jürgen W. Krebs, Switzerland 43.54% 11.69
Slide 20: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 21: Notes
Notes cap
Slide 22: Notes
Notes cap
Slide 23: Notes
Notes cap
Slide 24: Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations
Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
aap Implantate — Warburg Small Cap Selection Conference 2018 on 6ix